维普期刊资源整合服务平台（V6.5）

171篇 您的检索式：作者名="Azambuja E"

选中清除导出查看参考文献查看引证文献引用追踪共9页首页上一页第1页下一页末页 /9 跳转

	题名	作者	年代	出处	被引量
1	The17q12-q21amplicon:Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours显示文摘	Mano MS Rosa DD De Azambuja E	2007	Cancer Treat Rev2007，33，：	1
2	Pathogenicity of Bacillus thuringiensis isolated from two species of Acromyrmex (Hymenoptera,Formicidae)显示文摘	PINTO L M AZAMBUJA A O DIEHL E	2003	Braz J Biol2003，63，2：	1
3	Trastuzumabfor patients with HER2 positive breast cancer: delivery,duration and combination therapies显示文摘	Pinto AC Ades F de Azambuja E ef af	2013	Breast2013，，2：	1
4	HER-2 overexpression/ amplification and its interaction with taxane-based therapy in breast cancer 显示文摘	Azambuja E Durbecq V Rosa DD	2008	Ann Oncol2008，19，2：	1
5	Dissecting the heterogeneity of triple-negative breast cancer显示文摘	Metzger-Filho O Tutt A de Azambuja E	2012	J Clin Oncol2012，30，15：	1
6	Predictingthe efficacy of anthracyclines in breast cancer(BC)patients:Results of the neoadjuvant TOP trial显示文摘	Desmedt C Azambuja E Larsimont D	2009	J ClinOncol2009，27，15：	1
7	Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation显示文摘	Lothaire P de Azambuja E Dequanter D	2006	Head Neck2006，28，3：	1
8	Isolation of Serratia marc- escens in the midgut of Rhodnius prolixus: impact on the estab- lishment of the parasite Trypanosoma crazi in the vector 显示文摘	Azambuja P Feder D Gareia E S	2004	Exp Parasitol2004，107，12：	1
9	Targeting the PI3K/AKT/ mTOR and Raf/MEK/ERK pathways in the treatmem of breast cancer显示文摘	Saini K S Loi S de Azambuja E	2013	Cancer Treat Rev2013，39，8：	1
10	Corrosion inhibition of copper in chloride solutions by pyrazole 显示文摘	Geler E Azambuja D S	2000	Corros Sci2000，42，：	1
11	Enlarged electrochemical window in dialkyl-imidazolium cation based room-temperature air and water-stable molten salts 显示文摘	Suarez P A Z Selbach V M Dullius J E L Einloft S Piatnicki C M S Azambuja D S Souza R F D Dupont	1997	J Electrochim Acta1997，42，：	1
12	Angiogenesis and cancer:A cross-talk between basic science and clinical trials (the 'do ut des' paradigm)显示文摘	Gilberta GC Puglisi F Azambuja E	2006	Crit Rev Oncol Hematol2006，59，1：	1
13	Trastuzumab for early breast cancer: current status and future directions 显示文摘	Dinh P de Azambuja E Piocart - Gebhart MJ	2007	Clin Adv Hematol Oncol2007，5，9：	1
14	Review: side effects of approved molecular targeted therapies in solid cancers显示文摘	Widakowich C de Castro G Jr de Azambuja E	2007	Oncologist2007，12，12：	1
15	Ki-67 as a prog- nostic marker in early breast cancer: a meta-analysis of published studies involving 12155 patients 显示文摘	de Azambuja E Cardoso F de Casrto G Jr	2007	Br J Cancer2007，96，10：	1
16	Pathogenicity of Bacillus thuringieusis isolated from two species of Acromyrmex (Hymenoptera,Formicidae)显示文摘	Pinto L M Azambuja A O Diehl E	2003	Braz J Biol2003，63，2：	1
17	Angiogenesis and cancer: a cross-talk between basic science and clinical trials ( the “do ut des” paradigm) 显示文摘	de Castro Junior G Puglisi F de Azambuja E	2006	Crit Rev Oncol Hematol2006，59，：	1
18	Dissecting the heterogeneity of triple-negative breast cancer显示文摘	Metzger-Filho O Tutt A de Azambuja E	2012	J Clin Oncol2012，30，15：	1
19	Trastuzumab for early breast cancer: current status and future directions显示文摘	Dinh P de Azambuja E Piccart-Gebhart MJ	2007	Clin Adv tte- matol Oncol2007，5，9：	1
20	Lapatinib with Trastuzumab for HER2-positive early breast cancer (NeoALTYO) : Survival outcomes of a raudomised, open- label, multiceutre, phase 3 trim and their association with pathological complete response 显示文摘	de Azambuja E Holmes AP Piccart-Gebhart M	2014	Lancet Oncol2014，15，10：	1

返回顶部每页显示：

共9页首页上一页第1页下一页末页 /9 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示